← Back to Search

Treatment for Alagille Syndrome (LOGIC Trial)

N/A
Waitlist Available
Led By Lisa Henn, PhD
Research Sponsored by Arbor Research Collaborative for Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

Cholestasis is a condition in which bile is not properly transported from the liver to the small intestine. Cholestasis can be caused by an array of childhood diseases, including the genetic diseases Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, bile acid synthesis and metabolism defects, and progressive familial intrahepatic cholestasis (PFIC) or benign recurrent intrahepatic cholestasis(BRIC). This study will investigate the natural history and progression of the four previously mentioned cholestatic liver diseases to provide a better understanding of the causes and effects of the diseases.

Eligible Conditions
  • Alagille Syndrome
  • Alpha-1 Antitrypsin Deficiency
  • Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Arbor Research Collaborative for HealthLead Sponsor
20 Previous Clinical Trials
33,792 Total Patients Enrolled
1 Trials studying Alagille Syndrome
552 Patients Enrolled for Alagille Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,410 Previous Clinical Trials
4,323,216 Total Patients Enrolled
1 Trials studying Alagille Syndrome
552 Patients Enrolled for Alagille Syndrome
Lisa Henn, PhDPrincipal InvestigatorArbor Research Collaborative for Health
6 Previous Clinical Trials
6,114 Total Patients Enrolled
1 Trials studying Alagille Syndrome
552 Patients Enrolled for Alagille Syndrome
~358 spots leftby May 2029